

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/13100182>

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P 1 Lactam Moieties as l – Glutamine Replac...

ARTICLE in JOURNAL OF MEDICINAL CHEMISTRY · MAY 1999

Impact Factor: 5.45 · DOI: 10.1021/jm9805384 · Source: PubMed

CITATIONS

91

READS

28

20 AUTHORS, INCLUDING:



Peter S Dragovich

Genentech

82 PUBLICATIONS 2,203 CITATIONS

SEE PROFILE



Benjamin Joseph Burke

Pfizer

20 PUBLICATIONS 304 CITATIONS

SEE PROFILE



Tove Tuntland

Novartis Institutes for BioMedical Research (...)

52 PUBLICATIONS 1,717 CITATIONS

SEE PROFILE



James W Meador

Momenta

32 PUBLICATIONS 1,406 CITATIONS

SEE PROFILE

Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P₁ Lactam Moieties as L-Glutamine Replacements

Peter S. Dragovich,* Thomas J. Prins, Ru Zhou, Stephen E. Webber, Joseph T. Marakovits, Shella A. Fuhrman, Amy K. Patick, David A. Matthews, Caroline A. Lee, Clifford E. Ford, Benjamin J. Burke, Paul A. Rejto, Thomas F. Hendrickson, Tove Tuntland, Edward L. Brown, James W. Meador III, Rose Ann Ferre, James E. V. Harr, Maha B. Kosa, and Stephen T. Worland

Agouron Pharmaceuticals, Inc., 3565 General Atomics Court, San Diego, California 92121

Received September 25, 1998

The structure-based design, chemical synthesis, and biological evaluation of various human rhinovirus (HRV) 3C protease (3CP) inhibitors which incorporate P₁ lactam moieties in lieu of an L-glutamine residue are described. These compounds are comprised of a tripeptidyl or peptidomimetic binding determinant and an ethyl propenoate Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. The P₁-lactam-containing inhibitors display significantly increased 3CP inhibition activity along with improved antirhinoviral properties relative to corresponding L-glutamine-derived molecules. In addition, several lactam-containing compounds exhibit excellent selectivity for HRV 3CP over several other serine and cysteine proteases and are not appreciably degraded by a variety of biological agents. One of the most potent inhibitors (AG7088, mean antirhinoviral EC₉₀ \approx 0.10 μ M, n = 46 serotypes) is shown to warrant additional preclinical development to explore its potential for use as an antirhinoviral agent.

Introduction

The human rhinoviruses (HRVs) are members of the picornavirus family and are the single most significant cause of the common cold.^{1,2} We recently described the design and development of substrate-derived^{3,4} tripeptidyl HRV 3C protease (3CP) inhibitors which incorporate C-terminal Michael acceptor moieties (e.g., compound **1**, Figure 1, Table 1).^{5–7} These compounds irreversibly inhibit 3CP by forming a covalent adduct with the active site cysteine residue of the enzyme and exhibit antirhinoviral activity in cell culture. In addition, the preceding paper describes the modification of such molecules by the introduction of a P₂–P₃ ketomethylene dipeptide isostere into the inhibitor design.⁸ The resulting peptidomimetic compounds display substantially improved in vitro antiviral properties relative to the corresponding peptide-derived molecules. In an effort to further modify the structure of the initially studied inhibitor series, we sought to alter amide moieties other than that linking the P₂–P₃ amino acid residues of **1** without significantly interfering with 3CP recognition. The results of our efforts to derivatize the primary amide present in the P₁ Gln⁹ side chain of **1** are described below.

Inhibitor Design and Structure–Activity Studies

Analysis of the HRV-2 3CP–**1** X-ray crystal structure⁵ indicated that only the trans P₁ Gln amide hydrogen atom interacted with the protease while the cis NH was solvent-exposed (Figure 2). Thus, selective alkylation of the latter was envisioned to allow for amide modification without adversely affecting 3CP inhibition properties. However, a molecule containing a monomethylated P₁




Figure 1. Design of HRV 3CP inhibitors.

Table 1

compd no.	R ₁	R ₂	formula ^a	sero-type ^b	$k_{\text{obs}}/[\text{I}]$ (M ⁻¹ s ⁻¹) ^c	EC ₅₀ (μ M) ^c	CC ₅₀ (μ M) ^c
1	H	H	C ₃₂ H ₄₂ N ₄ O ₇	2	25 000	0.54	>320
2	CH ₃	H	C ₃₃ H ₄₄ N ₄ O ₇		2 000	1.6	>100
3	CH ₃	CH ₃	C ₃₄ H ₄₆ N ₄ O ₇		750	5.6	>100
					60	4.0	>100

^a Elemental analyses (C, H, N) of all compounds agreed to within $\pm 0.4\%$ of theoretical values. ^b Serotype-14 unless otherwise noted. ^c See ref 5 for assay method and error.

glutamine moiety (**2**)⁶ displayed drastically reduced 3CP inhibition activity relative to the nonalkylated inhibitor **1** (Figure 1, Table 1).¹⁰ A comparison of **1**, **2**, and the dimethylated analogue **3**⁶ (Figure 1, Table 1) suggested




Figure 2. Schematic diagram of **1** bound in the HRV-2 3CP active site.⁵ Hydrogen bonds are represented as dashed lines, and the residues which make up the enzyme binding subsites are depicted.

that the poor anti-3CP activity exhibited by **2** was primarily attributable to an unfavorable equilibrium in which the trans methyl amide isomer predominated over the desired cis isomer (Figure 3).¹¹ We therefore sought to enforce the cis amide geometry by the incorporation of a P₁ lactam moiety into the inhibitor design. Modeling studies (see below) utilizing the HRV-2 3CP-**1** crystal structure⁵ suggested that such a lactam moiety could be accommodated in the 3CP S₁ binding pocket and predicted the (*S*)-stereochemistry at the lactam α -carbon to be the most favorable for effective 3CP recognition (Figure 3).

In the event, the (*S*)- γ -lactam-containing compound **4** displayed dramatically improved inhibitory activity against 3CPs from several rhinovirus serotypes relative to the corresponding glutamine-derived molecule **1** (Tables 1 and 2). Equally important, inhibitor **4** also exhibited improved antiviral properties relative to **1** and was not cytotoxic in cell culture to the limits of its solubility.¹³ The corresponding (*S*)- δ -lactam-containing inhibitor **5** also displayed significantly improved anti-3CP and antiviral activity relative to **1**, while a molecule incorporating an (*R*)- γ -lactam (**6**) exhibited reduced 3CP inhibition properties in accordance with computational predictions (see below, Table 2). A similar reduction in anti-3CP activity was obtained by incorporation of a cyclic urea moiety into the inhibitor design (**7**). The poor inhibition properties of **7** relative to **4** paralleled reductions in anti-3CP activity observed previously with inhibitors containing acyclic P₁ urea functionalities.⁶



The promising antirhinoviral activity exhibited by the (*S*)- γ - and (*S*)- δ -lactam-containing Cbz-Leu-Phe-derived compounds prompted the incorporation of these lactam entities into other 3CP inhibitors. Thus, substitution of a P₃ Val amino acid residue in place of Leu (**8**, Table 2) significantly improved anti-3CP activity in direct analogy to structure–activity relationships observed for related glutamine-containing 3CP inhibitors.⁶ This result indicated that the P₁ lactam-containing compounds bound to 3CP in a manner similar to that observed for the corresponding glutamine-derived molecules and suggested that other beneficial modifications of the latter series might improve the former as well.¹⁴

Accordingly, the P₁ lactam moiety was incorporated into tripeptidyl molecules containing a P₃ Val amino acid residue and an N-terminal amide derived from 5-methylisoxazole-3-carboxylic acid (**9** and **10**, Table 3).¹⁵ The resulting compounds rapidly and irreversibly inhibited HRV-14 3CP and displayed very potent antiviral properties in cell culture. Inclusion of a Val-Phe ketomethylene dipeptide isostere⁸ in the inhibitor design resulted in slightly diminished anti-3CP activity but further improved antirhinoviral properties in cell culture (compare **9** with **11** and **10** with **12**, Table 3). Similar activity differences between ketomethylene- and peptide-derived 3CP inhibitors were previously observed during the examination of non-P₁-lactam-containing molecules.⁸ In addition to the compounds described above, a tripeptide-derived inhibitor which contained a P₃ tBuGly residue also exhibited impressive anti-3CP and antiviral properties (compound **13**, Table 3).

Two of the most active antiviral agents were also examined against multiple rhinovirus serotypes in cell culture (Table 4). The tripeptide-derived inhibitor **9** exhibited potent EC₉₀ antiviral activity against all serotypes tested.¹⁶ As anticipated from previous studies,⁸ the ketomethylene-containing molecule **11** displayed more potent EC₉₀ antiviral properties than the peptide **9**. This improvement, however, was not nearly as dramatic as that observed when examining P₁ glutamine-derived peptidyl and peptidomimetic 3CP inhibitors.⁸ A comparison of the lactam-containing molecule **11** with its glutamine analogue **14**⁸ indicated that incorporation of the P₁ lactam moiety into the inhibitor design improved EC₉₀ antiviral activity by a factor of between 8 and 16 (depending on HRV serotype). Similar improvements in antiviral activity were noted when comparing other lactam- and glutamine-containing molecules (data not shown). Compounds **9** and **11** rank among the most potent known antirhinoviral agents, and they compare favorably with the capsid-binding molecules Pirodavir¹⁷ and Pleconaril¹⁸ (Table 4).


Due to the encouraging antiviral activity exhibited by the compounds depicted in Table 3, several of their other biological properties were examined in anticipation of possible preclinical development efforts. One such property was the ability of the molecules to selectively inhibit HRV 3CP without affecting other proteolytic enzymes. None of the Michael acceptor-containing compounds examined in this study appreciably inhibited a variety of serine proteases when incubated at relatively high concentrations for 10–15 min (Table 5). However, measurable inhibition of the cysteine protease cathepsin B by the tripeptidyl molecule **1** was observed under the above assay conditions. In contrast, the more potent antirhinoviral agents described in this study (**9** and **11**) did not affect any of the nonrhinoviral cysteine proteases examined, suggesting that optimization of their 3CP inhibition properties also led to improvements in enzyme selectivity.

In addition to the selectivity studies described above, the stability of many 3CP inhibitors toward several biologically relevant agents was also examined. As was the case with previously examined irreversible 3CP inhibitors,⁵ the ethyl propenoate Michael acceptor was employed extensively in the current work due to its ease

**Figure 3.** Design of P₁-lactam-containing HRV 3CP inhibitors.**Table 2**

compd no.	R	X	n	formula ^a	serotype ^b	$k_{\text{obs}}/[\text{I}]$ (M ⁻¹ s ⁻¹) ^c	EC ₅₀ (μM) ^c	CC ₅₀ (μM) ^c
4	CH ₂ CH(CH ₃) ₂	(S)-CH	1	C ₃₄ H ₄₄ N ₄ O ₇ ·0.50H ₂ O	2	257 000	0.10	>100
5	CH ₂ CH(CH ₃) ₂	(S)-CH	2	C ₃₅ H ₄₆ N ₄ O ₇ ·0.50H ₂ O		31 000	ND	>100
6	CH ₂ CH(CH ₃) ₂	(R)-CH	1	C ₃₄ H ₄₄ N ₄ O ₇		18 000	1.6	>100
7	CH ₂ CH(CH ₃) ₂	N	1	C ₃₃ H ₄₃ N ₅ O ₇		10 900	0.60	>100
8	CH(CH ₃) ₂	(S)-CH	1	C ₃₃ H ₄₂ N ₄ O ₇		500 000	0.03	>100

^a Elemental analyses (C, H, N) of all compounds agreed to within ±0.4% of theoretical values. ^b Serotype-14 unless otherwise noted. ^c See ref 5 for assay method and error. ND = not determined.

Table 3


compd no.	R	X	n	formula ^a	$k_{\text{obs}}/[\text{I}]$ (M ⁻¹ s ⁻¹) ^{b,c}	EC ₅₀ (μM) ^{b,c}	CC ₅₀ (μM) ^c
9	CH(CH ₃) ₂	NH	1	C ₃₀ H ₃₈ FN ₅ O ₇	1 500 000	0.01	>100
10	CH(CH ₃) ₂	NH	2	C ₃₁ H ₄₀ FN ₅ O ₇	900 000	0.02	>100
11	CH(CH ₃) ₂	CH ₂	1	C ₃₁ H ₃₉ FN ₄ O ₇	1 090 000	0.005	>100
12	CH(CH ₃) ₂	CH ₂	2	C ₃₂ H ₄₁ FN ₄ O ₇	500 000	0.001	>100
13	C(CH ₃) ₃	NH	1	C ₃₁ H ₄₀ FN ₅ O ₇	980 000	0.01	>100




^a Elemental analyses (C, H, N) of all compounds agreed to within ±0.4% of theoretical values. ^b Serotype-14. ^c See ref 5 for assay method and error.

of preparation. However, a concern existed that this moiety might undergo facile *in vivo* metabolism, thereby compromising the usefulness of molecules in which it was incorporated.¹⁹ As expected based on previous studies,⁵ inhibitor **11** was rapidly degraded in rat plasma, presumably due to hydrolysis of the α,β-unsaturated ethyl ester present in the molecule (Table 6).²⁰ However, the compound was quite stable toward human and dog plasmas and exhibited negligible degradation in the presence of hydrolytic enzymes such as chymotrypsin and peptidase. In addition, the molecule was unaffected by prolonged exposure to high concentrations of dithiothreitol (5 mM), suggesting that the

inhibitor did not react readily with nonenzymatic thiols. Similar stability toward the various biological agents listed (and instability toward rat plasma) was noted for many other 3CP inhibitors related to the molecules described in this study (data not shown). Although the studies described above do not address every aspect of *in vivo* metabolism, they do examine some of the more obvious degradation events that might affect the compounds detailed in this work.

The extremely potent antirhinoviral activity displayed by compound **11**, along with its excellent protease selectivity, low cytotoxicity in cell culture, and stability toward various biological agents prompted its selection

Table 4. Antirhinoviral Activity of Selected 3CP Inhibitors against Several HRV Serotypes


Compd No.	R	X	EC ₉₀ vs Rhinovirus Serotype (μM) ^a			
			HRV-14	HRV-1A	HRV-2	HRV-10
14		CH ₂	0.32	0.63	0.28	0.79
11		CH ₂	0.020	0.041	0.030	0.10
9		NH	0.040	0.14	0.050	0.14
Pirodavir ^b	-	-	0.13	0.95	0.035	0.060
Pleconaril ^c	-	-	0.16	1.4	0.050	0.30

^a See ref 5 for assay method and error. ^b Provided by Janssen Pharmaceuticals. ^c Prepared as described in ref 18.

Table 5. Inhibition of Serine and Cysteine Proteases by Selected Antirhinoviral Agents

compd no. ^b	% activity remaining after 10–15 min ^a					
	thrombin	chymo-trypsin	trypsin	elastase	cathepsin B	calpain
1 ^c	101	96	98	92	39	100
9	103	101	100	100	96	100
11	100	100	100	99	98	100
13	101	97	95	96	81	100
DMSO	100	100	100	100	100	100

^a Each enzyme was present in the appropriate assay at ~10 nM.

^b Tested at 10 μM unless otherwise noted. ^c Tested at 2 μM.

Table 6. Stability of Compound **11** toward Various Biological Agents

biological agent ^a	half-life (min)
rat plasma	<2
dog plasma	>60
human plasma	>60
chymotrypsin	>60
peptidase	>60
dithiothreitol (5 mM)	>30

^a See the Experimental Section for assay conditions and details.

as a candidate for further development. This molecule (AG7088) is currently undergoing testing to evaluate its possible clinical use as an antirhinoviral agent, and additional data concerning these studies will be disclosed in due course.

Molecular Modeling Studies

Two related computational approaches were utilized to estimate the binding affinities of various lactam-containing molecules to HRV 3CP. The results of both methods are depicted in Table 7 and are compared with experimental values. Each analysis employed lactam model compounds constructed from the previously described HRV-2 3CP-1 complex.⁵ In the first approach, the expected covalent protein–inhibitor complex was examined, while in the second the noncovalent encounter complex between enzyme and ligand was studied.

Table 7. Computational Studies of P₁-Lactam-Containing HRV 3CP Inhibitors


compd no.	$k_{\text{obs}}/[\text{I}]$ (M ⁻¹ s ⁻¹)	relative rate	measured affinity ^a (kcal/mol)	predicted affinity (no. 1) ^{a,b} (kcal/mol)	predicted affinity (no. 2) ^{a,c} (kcal/mol)
1	25 000	1	0.0	0.0	0.0
4	257 000	10	-1.4	-2.0	-1.4
5	239 000	9.6	-1.3	-1.7	-1.0
6	18 000	0.72	0.20	0.7	5.9

^a Relative values; assumes changes in $k_{\text{obs}}/[\text{I}]$ values are representative of changes in ligand-3CP affinity. ^b Calculated using the covalent protein–ligand complex. ^c Calculated using the noncovalent protein–ligand encounter complex. See the Experimental Section for additional details.

The 3CP affinity of compound **1** was calculated in both analyses to serve as a reference, and the latter calculations also included an entropic correction to account for the expected differences in flexibility between lactam- and glutamine-containing molecules.²¹ As seen in Table 7, both methods qualitatively predicted the improved anti-3CP activity of (*S*)-lactam containing molecules **4** and **5** relative to glutamine-derived inhibitors such as **1**. Both methods also qualitatively anticipated the reduced 3CP affinity exhibited by the (*R*)-lactam containing compound **6**. Additional details of these molecular modeling studies are included in the Experimental Section.

Synthesis

The lactam-containing compounds utilized in this study were prepared by a variety of methods which incorporate several elements from previous syntheses of related 3CP inhibitors. The preparation of a tripeptidyl (*S*)-γ-lactam-containing inhibitor is illustrated in Scheme 1 by the synthesis of compound **4**. The known methyl ester **15**²² (derived from L-glutamic acid in four steps) was hydrolyzed under basic conditions to provide the corresponding carboxylic acid (**16**) in quantitative yield. This material was not purified, but was instead coupled with (*S*)-(-)-4-benzyl-2-oxazolidinone to give

Scheme 1^a

^a DMB = 2,4-dimethoxybenzyl. Reagents and conditions: (a) 3.0 equiv of NaOH, CH₃OH, 23 °C, 3.5 h, 100%; (b) 3.0 equiv of Et₃N, 1.0 equiv of *t*-BuCOCl, 1.1 equiv of LiCl, 0.95 equiv of (*S*)-(-)-4-benzyl-2-oxazolidinone, THF, 0→23 °C, 19 h, 83%; (c) 1.0 equiv of NaN(TMS)₂, 3.0 equiv of allyl iodide, THF, -78→-45 °C, 2 h, 55%; (d) O₃, 2.0 equiv of CH₃OH, CH₂Cl₂, -78 °C, then 10 equiv of Me₂S, 0 °C, 1 h; (e) 4.0 equiv of HCl·H₂N-DMB, 4.0 equiv of NaOAc, 2.0 equiv of NaBH₃CN, 2:1 THF:EtOH, 23 °C, 18 h; (f) 0.20 equiv of TsOH·H₂O, CH₃OH, 50 °C, 2.5 h, 44% from **18**; (g) 3.0 equiv of DMSO, 1.5 equiv of oxalyl chloride, 6.0 equiv of Et₃N, CH₂Cl₂, -78 °C, 1.5 h, 100%; (h) 1.0 equiv of NaN(TMS)₂, 1.0 equiv of (EtO)₂P(O)CH₂CO₂Et, THF, -78→0 °C, 45 min, 61%; (i) HCl, 1,4-dioxane, 23 °C, 1.5 h; (j) 1.3 equiv of Cbz-L-Leu-L-Phe-OH, 4.0 equiv of NMM, 1.7 equiv of HOBT, 1.7 equiv of EDC, CH₂Cl₂, 23 °C, 20 h, 70%; (k) 4.9 equiv of DDQ, 10:1 CHCl₃:H₂O, 50 °C, 8 h, 55%.



acyl oxazolidinone **17** in good yield.²³ Low-temperature alkylation of the sodium enolate derived from **17** with allyl iodide then provided the allyl derivative **18** after purification on silica gel.^{24,25} This material was converted to lactam **19** by ozonolysis and subsequent reductive amination of the resulting aldehyde (not shown) with 2,4-dimethoxybenzylamine. Lactam **19** was difficult to separate completely from contaminating (*S*)-(-)-4-benzyl-2-oxazolidinone, and the mixture of the two was typically hydrolyzed under mildly acidic conditions to provide the more easily purified amino alcohol **20**.

The conversion of **20** into inhibitor **4** then paralleled several previous syntheses of tripeptide-derived Michael acceptors quite closely.^{5,6} Thus, Swern oxidation²⁶ of **20** followed by olefination of the resulting aldehyde (**21**) provided the trans α,β -unsaturated ethyl ester **22** in moderate yield. As was observed previously,⁵ only minor amounts (<5%) of the corresponding cis olefin isomer were formed during the conversion of **21** to **22**. Acidic removal (HCl) of the Boc protecting group from **22** and carbodiimide-mediated coupling of the resulting amine hydrochloride salt with commercially available Cbz-L-Leu-L-Phe-OH afforded the tripeptidyl molecule **23** in good overall yield. The 2,4-dimethoxybenzyl moiety was removed from **23** by treatment with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) at elevated temperature to give γ -lactam-containing inhibitor **4** in moderate yield.²⁷ Alternatively, this deprotection could be accomplished by exposure of **23** to ceric ammonium nitrate (CAN).²⁸ In both cases, flash column chromatography was necessary to remove impurities generated during the deprotection reaction from the desired inhibitor. The (*R*)- γ -lactam-containing compound **6** was prepared in a manner that was completely

analogous to the synthesis of **4** described above, with the exception that (*R*)-(+)-4-benzyl-2-oxazolidinone was employed for coupling with carboxylic acid **16** (data not shown).²⁹


The preparation of an intermediate required for the synthesis of inhibitors incorporating a P₁ (*S*)- δ -lactam moiety is illustrated in Scheme 2. Hydroboration of the allyl derivative **18** described in Scheme 1 afforded alcohol **24** in good yield after oxidative workup and chromatographic purification. This material was treated with SO₃·pyridine, and the resulting aldehyde (not shown) was condensed with 2,4-dimethoxybenzylamine utilizing the reductive amination conditions described above for the preparation of compound **19** to give intermediate **25**. As before, **25** was difficult to separate from the (*S*)-(-)-4-benzyl-2-oxazolidinone produced during lactam formation. Impure **25** was therefore hydrolyzed under acidic conditions to give alcohol **26** which could be satisfactorily purified by flash column chromatography. Swern oxidation²⁶ of **26** and subsequent olefination of the resulting aldehyde (**27**) then afforded α,β -unsaturated ester **28**. This intermediate was converted into inhibitors **5**, **10**, and **12** by methods that were completely analogous to other syntheses reported in this work (cf., Schemes 1, 4, and 5).

The preparation of the cyclic-urea-containing inhibitor **7** is depicted in Scheme 3. Attempts to synthesize the P₁ intermediate corresponding to **22** and **28** (Schemes 1 and 2) were unsuccessful in the case of the cyclic urea, and an alternate approach to the target compound was therefore utilized. Accordingly, olefination of the known tripeptide **29**³⁰ uneventfully provided the α,β -unsaturated ester **30**. Removal of the Boc protecting group from **30** and coupling of the resulting amine salt with N-Boc-

Scheme 2^aScheme 3^a


2-aminoethanal under reductive amination conditions provided the protected diamine compound **31** in moderate yield. Boc deprotection (TFA), neutralization of the amine salt thus obtained, and subsequent exposure of the free diamine to 1,1'-carbonyldiimidazole afforded the cyclic-urea-containing inhibitor **7** in good yield.

Inhibitors **9** and **11** were prepared by derivatization of intermediate **22** with amino acid residues or a ketomethylene dipeptide isostere, respectively. Thus, acidic deprotection (HCl) of **22** and carbodiimide-mediated coupling of the resulting amine salt with Boc-L-Phe(4-F)-OH afforded the dipeptide product **32** in moderate yield (Scheme 4). A second HCl deprotection and subsequent coupling with Boc-L-Val-OH then pro-

Scheme 4^a


vided the corresponding tripeptide **33** (not shown). This material was also deprotected under acidic conditions (HCl), and the amine hydrochloride thus produced was derivatized with 5-methylisoxazole-3-carbonyl chloride to give intermediate **34** in moderate overall yield. As described for the preparation of **4** above, treatment of **34** with DDQ at elevated temperature provided the tripeptidyl inhibitor **9** after purification on silica gel. Similarly, coupling of the amine hydrochloride salt derived from HCl deprotection of **22** with the ketomethylene dipeptide isostere **35**⁸ (used in crude form) gave intermediate **36** in moderate overall yield (Scheme 5). This material was transformed into inhibitor **11** in a manner analogous to that used for the conversion of intermediate **33** to inhibitor **9** described above.

vided the corresponding tripeptide **33** (not shown). This material was also deprotected under acidic conditions (HCl), and the amine hydrochloride thus produced was derivatized with 5-methylisoxazole-3-carbonyl chloride to give intermediate **34** in moderate overall yield. As described for the preparation of **4** above, treatment of **34** with DDQ at elevated temperature provided the tripeptidyl inhibitor **9** after purification on silica gel. Similarly, coupling of the amine hydrochloride salt derived from HCl deprotection of **22** with the ketomethylene dipeptide isostere **35**⁸ (used in crude form) gave intermediate **36** in moderate overall yield (Scheme 5). This material was transformed into inhibitor **11** in a manner analogous to that used for the conversion of intermediate **33** to inhibitor **9** described above.



Conclusions

The studies presented above illustrate how the incorporation of P_1 lactam glutamine replacements into substrate-derived, irreversible human rhinovirus 3C protease (3CP) inhibitors substantially improves the anti-3CP and antiviral activity of such compounds. Both peptidyl and peptidomimetic molecules benefit from such incorporation, and the resulting optimized inhibitors rank among the most potent antirhinoviral agents described in the literature to date. In addition, most of the compounds presented in this work display excellent selectivity for HRV 3CP over other serine and cysteine

Scheme 5^a

^a DMB = 2,4-dimethoxybenzyl. Reagents and conditions: (a) HCl, 1,4-dioxane, 23 °C, 1.5 h; (b) 1.4 equiv of **35**,⁸ 4.0 equiv of NMM, 1.7 equiv of HOBT, 1.7 equiv of EDC, CH₂Cl₂, 23 °C, 18 h, 63%; (c) HCl, 1,4-dioxane, 23 °C, 1.5 h; (d) 2.2 equiv of NMM, 1.1 equiv of 5-methylisoxazole-3-carbonyl chloride, CH₂Cl₂, 0–23 °C, 1 h, 85%; (e) 1.4 equiv of DDQ, 10:1 CHCl₃:H₂O, reflux, 20 h, 39%.

proteases and exhibit good stability toward a variety of biological agents. The above studies led to the selection of one inhibitor (compound **11**, AG7088) as a development candidate, and the molecule is currently undergoing testing to evaluate its potential clinical use as an antirhinoviral agent.

Experimental Section

General descriptions of experimental procedures, reagent purifications, and instrumentation along with conditions and uncertainties for enzyme and antiviral assays are provided elsewhere.⁵ ¹H NMR chemical shifts are reported in ppm (δ) downfield relative to internal tetramethylsilane, and coupling constants are given in hertz. A simplified naming system employing amino acid abbreviations is used to identify some intermediates and final products. When utilizing this naming system, italicized amino acid abbreviations represent modifications at the C-terminus of that residue where acrylic acid esters are reported as "E" (trans) propenoates. In addition, the terminology "AA₁Ψ[COCH₂]-AA₂" indicates that, for any peptide sequence, two amino acids (AA₁ and AA₂) usually linked by an amide bond are replaced by a ketomethylene dipeptide isostere. The following abbreviations also apply: HATU [*O*-(7-azabenzotriazol-1-yl)-*N,N,N,N*-tetramethyluronium hexafluorophosphate], HOBT [1-hydroxybenzotriazole hydrate], EDC [1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride], CDI [1,1'-carbonyldiimidazole], MTBE [*tert*-butyl methyl ether], DDQ [2,3-dichloro-5,6-dicyano-1,4-benzoquinone], (S)-Pyrrol-Ala [(2*S*,3'*S*)-2-amino-3-(2'-oxopyrrolidin-3'-yl)propionic acid], (S)-Piper-Ala [(2*S*,3'*S*)-2-amino-3-(2'-oxopiperidin-3'-yl)propionic acid]. Pirodavar was kindly provided by Janssen Pharmaceuticals. Pleconaril was prepared as described in the literature.¹⁸

(4*S*)-4-(2'-Carboxyethyl)-2,2-dimethyloxazolidine-3-carboxylic Acid *tert*-Butyl Ester (16). Sodium hydroxide (27 mL of a 4.0 M solution in H₂O, 108 mmol, 3.0 equiv) was added to a solution of (4*S*)-4-(2-methoxycarbonyl)-2,2-dimethyloxazolidine-3-carboxylic acid *tert*-butyl ester **15**²² (10.5 g, 36.5 mmol, 1 equiv) in CH₃OH (150 mL), and the resulting cloudy reaction mixture was stirred at 23 °C for 3.5 h. The mixture was concentrated under reduced pressure to ~30 mL volume and then was partitioned between 0.5 M HCl (150 mL) and EtOAc (2 × 150 mL). The combined organic layers were dried

over MgSO₄ and were gravity-filtered. The filtrate was concentrated under reduced pressure and the residue dried under vacuum to afford **16** (10.0 g, 100% crude yield) as a colorless oil. This material was used without further purification: ¹H NMR (CDCl₃, mixture of isomers) δ 1.49 (s), 1.57 (s), 1.60 (s), 1.84–2.05 (m), 2.39–2.41 (m), 3.71–3.74 (m), 3.91–4.05 (m).

(4*S*,4'*S*)-4-[3'-(4'-Benzyl-2'-oxo-oxazolidin-3'-yl)-3'-oxopropyl]-2,2-dimethyloxazolidine-3-carboxylic Acid *tert*-Butyl Ester (17). Triethylamine (8.87 mL, 63.6 mmol, 3.0 equiv) and pivaloyl chloride (2.61 mL, 21.2 mmol, 1.0 equiv) were added sequentially to a solution of **16** (5.80 g, 21.2 mmol, 1 equiv) in THF (450 mL) at 0 °C. The cloudy reaction mixture was stirred at 0 °C for 3.5 h, and then lithium chloride (0.988 g, 23.3 mmol, 1.1 equiv) and (S)-(-)-4-benzyl-2-oxazolidinone (3.57 g, 20.1 mmol, 0.95 equiv) were added sequentially. After warming to 23 °C and being stirred for 19 h, the reaction mixture was partitioned between 0.5 M HCl (150 mL) and EtOAc (2 × 150 mL). The combined organic layers were washed with half-saturated Na₂CO₃ (150 mL), dried over MgSO₄, and gravity-filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by flash column chromatography (30% EtOAc in hexanes) to give **17** (7.17 g, 83%) as a colorless oil which slowly crystallized over 7 days: mp = 60–64 °C; *R*_f = 0.69 (50% EtOAc in hexanes); IR (cm⁻¹) 2978, 1783, 1694; ¹H NMR (CDCl₃, mixture of isomers) δ 1.49 (s), 1.59 (s), 1.63 (s), 2.01–2.10 (m), 2.76 (dd, *J* = 13.5, 9.8), 2.82–3.13 (m), 3.30–3.41 (m), 3.76–3.82 (m), 3.90 (s, br), 3.97 (dd, *J* = 9.0, 5.6), 4.10–4.19 (m), 4.63–4.71 (m), 7.22–7.36 (m). Anal. (C₂₃H₃₂N₂O₆) C, H, N.

(2'*S*,4*S*,4'*S*)-4-[2'-(4'-Benzyl-2'-oxo-oxazolidine-3'-carbonyl)-pent-4'-enyl]-2,2-dimethyloxazolidine-3-carboxylic Acid *tert*-Butyl Ester (18). A solution of **17** (7.17 g, 16.6 mmol, 1 equiv) in THF (50 mL) was added to a solution of sodium bis(trimethylsilyl)amide (16.6 mL of a 1.0 M solution in THF, 16.6 mmol, 1.0 equiv) in the same solvent (150 mL) at -78 °C. The reaction mixture was stirred for 20 min at -78 °C, and then allyl iodide (4.55 mL, 49.8 mmol, 3.0 equiv) was added. After being stirred an additional 3 h at -78 °C, the reaction mixture was maintained at -45 °C for 2 h and then was partitioned between a 2:1 mixture of half-saturated NH₄Cl and 5% Na₂S₂O₃ (300 mL) and a 1:1 mixture of EtOAc and hexanes (2 × 200 mL). The combined organic layers were washed with H₂O (200 mL), dried over MgSO₄, and gravity-filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by flash column chromatography (15% EtOAc in hexanes) to provide **18** (4.29 g, 55%) as a colorless oil: *R*_f = 0.44 (30% EtOAc in hexanes); IR (cm⁻¹) 2978, 1780, 1695; ¹H NMR (CDCl₃, mixture of isomers) δ 1.45 (s), 1.49 (s), 1.68–1.80 (m), 2.13–2.47 (m), 2.49–2.67 (m), 3.32 (dd, *J* = 13.4, 3.1), 3.69–3.97 (m), 4.11–4.21 (m), 4.66–4.74 (m), 5.06–5.13 (m), 5.74–5.88 (m), 7.20–7.36 (m). Anal. (C₂₆H₃₆N₂O₆) C, H, N.

(1*S*,3'*S*)-{2-[1'-(2'',4''-Dimethoxybenzyl)-2'-oxo-pyrrolidin-3'-yl]-1-hydroxymethylethyl}-carbamic Acid *tert*-Butyl Ester (20). Ozone was bubbled through a solution of **18** (4.29 g, 9.08 mmol, 1 equiv) in CH₂Cl₂ (200 mL) containing CH₃OH (0.735 mL, 18.1 mmol, 2.0 equiv) at -78 °C until a blue color persisted. The reaction mixture was then purged with argon until it became colorless. Methyl sulfide (6.67 mL, 90.8 mmol, 10 equiv) was added, and the mixture was stirred at -78 °C for 3.5 h and then was maintained at 0 °C for an additional 1 h. After partitioning the reaction mixture between H₂O (200 mL) and a 1:1 mixture of EtOAc and hexanes (2 × 200 mL), the combined organic layers were dried over MgSO₄ and were gravity-filtered. The filtrate was concentrated under reduced pressure, and the residue was immediately utilized without further purification.

The above residue was dissolved in a 2:1 mixture of THF and EtOH (240 mL) at 23 °C, and 2,4-dimethoxybenzylamine hydrochloride (7.40 g, 36.3 mmol, 4.0 equiv), sodium acetate (2.98 g, 36.2 mmol, 4.0 equiv), and sodium cyanoborohydride (1.14 g, 18.1 mmol, 2.0 equiv) were added sequentially. The resulting suspension was stirred for 18 h at 23 °C and then was partitioned between 0.5 M HCl (400 mL) and EtOAc (2 ×

200 mL). The combined organic layers were washed with half-saturated NaHCO_3 (300 mL), dried over Na_2SO_4 , and concentrated under reduced pressure. The residue was passed through a short silica gel column (eluting with 50% EtOAc in hexanes) to give **19** contaminated with (S)-(-)-4-benzyl-2-oxazolidinone.

This material was dissolved in CH_3OH (100 mL), and $\text{TsOH} \cdot \text{H}_2\text{O}$ (0.345 g, 1.81 mmol, 0.20 equiv) was added. The reaction mixture was heated to 50 °C and was maintained at that temperature for 2.5 h. After cooling to 23 °C, the reaction mixture was concentrated under reduced pressure to ~20 mL volume and was partitioned between half-saturated NaHCO_3 (150 mL) and a 9:1 mixture of CH_2Cl_2 and CH_3OH (2×150 mL). The combined organic layers were dried over Na_2SO_4 and were concentrated under reduced pressure. Purification of the residue by flash column chromatography (3% CH_3OH in CH_2Cl_2) afforded **20** (1.62 g, 44% from **18**) as a foam: $R_f = 0.03$ (50% EtOAc in hexanes); IR (cm^{-1}) 3328, 1669; ^1H NMR (CDCl_3) δ 1.44 (s, 9H), 1.50–1.75 (m, 2H), 1.90–2.00 (m, 1H), 2.17–2.27 (m, 1H), 2.52–2.62 (m, 1H), 3.14–3.24 (m, 2H), 3.51–3.65 (m, 3H), 3.70–3.78 (m, 1H), 3.80 (s, 6H), 4.35 (d, 1H, $J = 14.3$), 4.48 (d, 1H, $J = 14.3$), 5.51–5.54 (m, 1H), 6.42–6.46 (m, 2H), 7.09–7.12 (m, 1H). Anal. ($\text{C}_{21}\text{H}_{32}\text{N}_2\text{O}_6$) C, H, N.

Ethyl-3-{Boc-L-[(N-2,4-dimethoxybenzyl)-(S)-Pyrrol-Ala]}-E-propenoate (22). DMSO (0.270 mL, 3.80 mmol, 3.0 equiv) was added dropwise to a –78 °C solution of oxalyl chloride (0.166 mL, 1.90 mmol, 1.5 equiv) in CH_2Cl_2 (14 mL). The reaction mixture was stirred 20 min at –78 °C and then a solution of **20** (0.518 g, 1.27 mmol, 1 equiv) in CH_2Cl_2 (13 mL) was added via cannula along the side of the reaction vessel. After an additional 20 min, triethylamine (1.06 mL, 7.60 mmol, 6.0 equiv) was added dropwise, and the reaction mixture was stirred for 1.5 h at –78 °C. Acetic acid (0.479 mL, 8.37 mmol, 6.6 equiv) was then added, and the reaction mixture was warmed to 0 °C for 5 min, then diluted with MTBE (200 mL), and washed with water (25 mL), saturated NaHCO_3 (25 mL), and brine (25 mL). The organic phase was dried over Na_2SO_4 and was concentrated to provide **21** as a white foam (0.516 g, 100%). This material was used without further purification.

Sodium bis(trimethylsilyl)amide (1.23 mL of a 1.0 M solution in THF, 1.23 mmol, 1.0 equiv) was added to a solution of triethyl phosphonoacetate (0.244 mL, 1.23 mmol, 1.0 equiv) in THF (15 mL) at –78 °C, and the resulting mixture was stirred for 20 min at that temperature. A solution of crude **21** (prepared above, 0.500 g, 1.23 mmol, 1 equiv) in THF (13 mL) was added via cannula along the side of the reaction vessel, and the resulting mixture was stirred for 45 min at –78 °C, warmed to 0 °C for 7 min, then was partitioned between 0.5 M HCl (20 mL) and MTBE (2×50 mL). The combined organic layers were dried over MgSO_4 and were concentrated. Purification of the residue by flash column chromatography (60% EtOAc in hexanes) provided **22** (0.356 g, 61%) as a white foam: $R_f = 0.43$ (60% EtOAc in hexanes); IR (cm^{-1}) 3307, 1708, 1678; ^1H NMR (CDCl_3) δ 1.28 (t, 3H, $J = 7.2$), 1.43 (s, 9H), 1.52–1.70 (m, 2H), 1.98–2.09 (m, 1H), 2.21–2.34 (m, 1H), 2.48–2.59 (m, 1H), 3.16–3.24 (m, 2H), 3.80 (s, 6H), 4.18 (q, 2H, $J = 7.2$), 4.27–4.40 (m, 1H), 4.41 (s, 2H), 5.40 (d, 1H, $J = 8.1$), 5.95 (dd, 1H, $J = 15.6$, 1.6), 6.41–6.48 (m, 2H), 6.86 (dd, 1H, $J = 15.6$, 5.3), 7.08–7.13 (m, 1H). Anal. ($\text{C}_{25}\text{H}_{36}\text{N}_2\text{O}_7 \cdot 0.25\text{H}_2\text{O}$) C, H, N.

Ethyl-3-{Cbz-L-Leu-L-Phe-L-[(N-2,4-dimethoxybenzyl)-(S)-Pyrrol-Ala]}-E-propenoate (23). A solution of HCl in 1,4-dioxane (4.0 M, 4 mL) was added to a solution of **22** (0.139 g, 0.292 mmol, 1 equiv) in the same solvent (4 mL) at 23 °C. After the mixture was stirred for 1.5 h at that temperature, the volatiles were evaporated to give the crude amine hydrochloride salt. This material was dissolved in CH_2Cl_2 (7 mL), and Cbz-L-Leu-L-Phe-OH (0.156 g, 0.378 mmol, 1.3 equiv), 4-methylmorpholine (0.128 mL, 1.16 mmol, 4.0 equiv), HOBt (0.067 g, 0.50 mmol, 1.7 equiv) and EDC (0.095 g, 0.50 mmol, 1.7 equiv), were added sequentially. After being stirred for 20 h at 23 °C, the reaction mixture was partitioned between brine (15 mL) and a 1:9 mixture of CH_3OH and CH_2Cl_2 (3×25 mL).

The combined organic layers were dried over Na_2SO_4 and were concentrated. Purification of the residue by flash column chromatography (60% EtOAc in hexanes) provided **23** (0.158 g, 70%) as a tan foam: $R_f = 0.30$ (5% CH_3OH in CH_2Cl_2); IR (cm^{-1}) 3289, 1713, 1655; ^1H NMR (CDCl_3) δ 0.87–0.92 (m, 6H), 1.28 (t, 3H, $J = 7.2$), 1.46–1.68 (m, 5H), 1.74–1.86 (m, 1H), 1.97–2.19 (m, 2H), 3.02 (dd, 1H, $J = 13.7$, 5.6), 3.11–3.24 (m, 3H), 3.78 (s, 3H), 3.79 (s, 3H), 4.17 (q, 2H, $J = 7.2$), 4.20–4.30 (m, 2H), 4.35–4.45 (m, 2H), 4.82–4.90 (m, 1H), 5.07 (d, 1H, $J = 12.3$), 5.13 (d, 1H, $J = 12.3$), 5.36 (d, 1H, $J = 7.8$), 5.82 (dd, 1H, $J = 15.6$, 1.2), 6.42–6.46 (m, 2H), 6.72 (dd, 1H, $J = 15.6$, 5.3), 6.88 (d, 1H, $J = 8.7$), 7.09 (d, 1H, $J = 9.0$), 7.13–7.20 (m, 5H), 7.29–7.37 (m, 5H), 8.09 (d, 1H, $J = 6.5$). Anal. ($\text{C}_{43}\text{H}_{54}\text{N}_4\text{O}_9 \cdot 0.5\text{H}_2\text{O}$) C, H, N.

Ethyl-3-{Cbz-L-Leu-L-Phe-L-[(S)-Pyrrol-Ala]}-E-propenoate (4). DDQ (0.066 g, 0.29 mmol, 1 equiv) and **23** (0.225 g, 0.291 mmol, 1.0 equiv) were combined in a mixture of CHCl_3 (4 mL) and water (0.4 mL). After the mixture was stirred for 2 h in a 50 °C oil bath, additional DDQ (0.095 g, 0.42 mmol, 1.4 equiv) was added. After 2 h more at 50 °C, a third portion of DDQ (0.099 g, 0.44 mmol, 1.5 equiv) was added. The reaction mixture was stirred for 2 h at 50 °C, and then DDQ (0.065 g, 0.29 mmol, 1.0 equiv) was added for the fourth time. After stirring for 2 h more at 50 °C, the reaction mixture was allowed to cool overnight, then was diluted with EtOAc (250 mL), and washed with saturated NaHCO_3 (40 mL) and brine (25 mL). The organic phase was dried over Na_2SO_4 and was concentrated. Purification of the residue by flash column chromatography (2.4% CH_3OH in CH_2Cl_2) provided **4** (0.100 g, 55%) as a white foam: $R_f = 0.26$ (5% CH_3OH in CH_2Cl_2); IR (cm^{-1}) 3278, 1690, 1637; ^1H NMR (CDCl_3) δ 0.85–0.92 (m, 6H), 1.28 (t, 3H, $J = 7.2$), 1.39–1.65 (m, 4H), 1.68–1.93 (m, 2H), 2.08–2.20 (m, 1H), 2.27–2.38 (m, 1H), 3.02–3.13 (m, 2H), 3.24–3.32 (m, 2H), 4.11–4.20 (m, 1H), 4.18 (q, 2H, $J = 7.2$), 4.47–4.58 (m, 1H), 4.81–4.89 (m, 1H), 5.05 (d, 1H, $J = 12.1$), 5.12 (d, 1H, $J = 12.1$), 5.26 (d, 1H, $J = 8.1$), 5.78 (dd, 1H, $J = 15.7$, 1.2), 6.23 (s, 1H), 6.72 (dd, 1H, $J = 15.7$, 5.3), 7.13–7.25 (m, 6H), 7.30–7.37 (m, 5H), 7.54 (d, 1H, $J = 7.2$). Anal. ($\text{C}_{34}\text{H}_{44}\text{N}_4\text{O}_7 \cdot 0.5\text{H}_2\text{O}$) C, H, N.

(2'S,4'S,4''S)-4-[2'-(4''-Benzyl-2''-oxo-oxazolidine-3''-carbonyl)-5'-hydroxypentyl]-2,2-dimethyloxazolidine-3-carboxylic Acid tert-Butyl Ester (24). A solution of borane-tetrahydrofuran complex (0.96 mL of a 1.0 M solution in THF, 0.96 mmol, 1.0 equiv) was added to a 0 °C solution of **18** (0.455 g, 0.963 mmol, 1 equiv) in THF (3 mL). After the mixture was stirred for 30 min, water (3 mL) and sodium perborate tetrahydrate (0.148 g, 0.962 mmol, 1.0 equiv) were added and the ice bath was removed. After an additional hour, the reaction mixture was diluted with MTBE (125 mL) and was washed with water (15 mL) and brine (2×15 mL). The combined organic layers were dried over Na_2SO_4 and were concentrated. Purification of the residue by flash column chromatography (50% EtOAc in hexanes) provided **24** (0.339 g, 72%) as a colorless glass: $R_f = 0.41$ (50% EtOAc in hexanes); IR (cm^{-1}) 3486, 1780, 1693; ^1H NMR (CDCl_3 , mixture of isomers) δ 1.42–1.85 (m), 2.13–2.24 (m), 2.70 (dd, $J = 13.1$, 10.0), 3.29–3.38 (m), 3.61–4.22 (m), 4.63–4.76 (m), 7.19–7.38 (m). Anal. ($\text{C}_{26}\text{H}_{38}\text{N}_2\text{O}_7 \cdot 0.5\text{H}_2\text{O}$) C, H, N.

(1S,3'S)-2-[1'-(2'',4''-Dimethoxybenzyl)-2'-oxo-piperidin-3'-yl]-1-hydroxymethylethyl-carbamic Acid tert-Butyl Ester (26). A solution of sulfur trioxide-pyridine complex (5.04 g, 31.67 mmol, 4.0 equiv) in DMSO (150 mL) was added to an ice-cooled solution of **24** (3.88 g, 7.92 mmol, 1 equiv) in triethylamine (2.75 mL, 28.51 mmol, 3.6 equiv) at a rate which maintained the reaction temperature between 8 and 17 °C. The resulting mixture was then stirred at 23 °C for 3 h, cooled to 0 °C, and was quenched by the addition of H_2O (150 mL). The quenched reaction mixture was extracted with EtOAc (2×150 mL), and the combined organic layers were washed with 5% citric acid (100 mL) and brine (100 mL), then were dried over Na_2SO_4 , and concentrated. The residue was dried further under vacuum to give a white foam (3.53 g).

To a solution of this material (3.53 g, 7.22 mmol, 1 equiv) in a 2:1 mixture of THF and EtOH (120 mL) were added 2,4-

dimethoxybenzylamine hydrochloride (5.88 g, 28.89 mmol, 4.0 equiv), NaOAc (2.37 g, 28.89 mmol, 4.0 equiv), and NaBH₃CN (0.908 g, 14.45 mmol, 2.0 equiv) at 23 °C. The reaction mixture was stirred 20 h at 23 °C and then was diluted with MTBE (200 mL). The organic layer was washed with 10% KHSO₄ (100 mL), saturated NaHCO₃ (100 mL), and brine (100 mL), dried over Na₂SO₄, and concentrated to give **25** as a pale yellow foam. This material was utilized without further purification.

p-Toluenesulfonic acid monohydrate (0.275 g, 1.44 mmol, 0.20 equiv) was added to a solution of crude **25** (3.34 g, 7.22 mmol, 1 equiv) in CH₃OH (50 mL) at 23 °C. The reaction mixture was maintained at 50 °C for 2.5 h and then was partitioned between CH₂Cl₂ (100 mL) and saturated NaHCO₃ (100 mL). The organic layer was dried over Na₂SO₄ and was concentrated. Purification of the residue by flash column chromatography (3% CH₃OH in CH₂Cl₂) afforded **26** (1.33 g, 44% from **24**) as a white foam: ¹H NMR (CDCl₃) δ 1.44 (s, 9H), 1.71–1.85 (m, 2H), 1.92–1.98 (m, 2H), 2.40–2.48 (m, 1H), 2.71–2.78 (m, 1H), 3.19–3.32 (m, 2H), 3.45–3.69 (m, 4H), 4.11–4.20 (m, 2H), 4.68 (m, 1H), 5.47 (m, 1H), 6.44 (s, 1H), 7.20–7.33 (m, 2H).

Ethyl-3-[(Boc-L-[(N-2,4-dimethoxybenzyl)-(S)-Piper-Ala]]-E-propenoate (28). DMSO (0.133 mL, 1.87 mmol, 4.0 equiv) was added dropwise to a –78 °C solution of oxalyl chloride (0.123 mL, 1.41 mmol, 3.0 equiv) in CH₂Cl₂ (7 mL). The reaction mixture was stirred 20 min at –78 °C, and then a solution of **26** (0.198 g, 0.468 mmol, 1 equiv) in CH₂Cl₂ (5 mL) was added via cannula along the side of the reaction vessel. After an additional 20 min, triethylamine (0.327 mL, 2.34 mmol, 5.0 equiv) was added dropwise, and the reaction mixture was maintained at –78 °C for 1.5 h. Acetic acid (0.148 mL, 2.59 mmol, 5.5 equiv) was added, and the reaction mixture was warmed to 0 °C for 5 min, then was diluted with MTBE (50 mL), and was washed with water (15 mL), saturated NaHCO₃ (15 mL), and brine (15 mL). The organic phase was dried over Na₂SO₄ and was concentrated to provide **27** as a foam which was used without further purification.

Sodium bis(trimethylsilyl)amide (0.468 mL of a 1.0 M solution in THF, 0.468 mmol, 1.0 equiv) was added to a solution of triethyl phosphonoacetate (0.093 mL, 0.47 mmol, 1.0 equiv) in THF (5 mL) at –78 °C, and the resulting solution was stirred for 20 min at that temperature. A solution of **27** (0.468 mmol, 1 equiv) in THF (4 mL) was added via cannula along the side of the reaction vessel, and the reaction mixture was stirred for 45 min at –78 °C, then warmed to 0 °C for 7 min, and was partitioned between 0.5 M HCl (20 mL) and MTBE (2 × 50 mL). The combined organic layers were dried over MgSO₄ and were concentrated. Purification of the residue by flash column chromatography (40% EtOAc in hexanes) provided **28** (0.110 g, 48%) as a white foam: *R*_f = 0.29 (40% EtOAc in hexanes); IR (cm^{–1}) 3296, 1716, 1616; ¹H NMR (CDCl₃) δ 1.28 (t, 3H, *J* = 7.2), 1.42–1.87 (m, 4H), 1.44 (s, 9H), 2.03–2.24 (m, 2H), 2.36–2.46 (m, 1H), 3.16–3.30 (m, 2H), 3.79 (s, 6H), 4.18 (q, 2H, *J* = 7.2), 4.26–4.38 (m, 1H), 4.53 (s, 2H), 5.50 (d, 1H, *J* = 7.8), 5.95 (dd, 1H, *J* = 15.6, 1.6), 6.42–6.48 (m, 2H), 6.86 (dd, 1H, *J* = 15.6, 5.1), 7.08–7.15 (m, 1H). Anal. (C₂₆H₃₈N₂O₇·0.25H₂O) C, H, N.

Ethyl-3-[Cbz-L-Leu-L-Phe-L-N-Boc-aminoAla]-E-propenoate (30). (Carbethoxymethylene)triphenylphosphorane (1.20 g, 3.28 mmol, 1.2 equiv) was added to a solution of **29**³⁰ (1.60 g, 2.73 mmol, 1 equiv) in THF (55 mL), and the reaction mixture was stirred at 23 °C overnight. The volatiles were then removed under reduced pressure, and the residue was purified by flash column chromatography (gradient elution, 0→1.5% CH₃OH in CH₂Cl₂) to give **30** (0.968 g, contaminated with triphenylphosphine oxide). This material was used without further purification.

Ethyl-3-[Cbz-L-Leu-L-Phe-L-(2-Boc-2-aminoethyl)aminoAla]-E-propenoate (31). A solution of HCl in 1,4-dioxane (4.0 M, 10 mL) was added to a solution of **30** (0.95 g, 1.46 mmol, 1 equiv) in the same solvent (20 mL) at 23 °C. The reaction mixture was stirred at that temperature for 1.5 h, and then additional HCl in 1,4-dioxane (4.0 M, 10 mL) was added. After

the mixture was stirred overnight, the volatiles were removed under reduced pressure and the residue was triturated with Et₂O (20 mL). The resulting solids were collected by vacuum filtration and were washed with Et₂O (3 × 10 mL) to give the crude amine salt (0.63 g 73%, 1.05 mmol).

This material was dissolved in CH₃OH (10 mL) at 23 °C, and N-Boc-2-aminoethanal (Aldrich, 0.19 g, 1.16 mmol, 1.1 equiv) and NaBH₃CN (0.069 g, 1.05 mmol, 1.0 equiv) were added sequentially. The reaction mixture was stirred at 23 °C overnight and then was concentrated. The residue was dissolved in EtOAc (25 mL), and the organic layer was washed with water (25 mL) and brine (25 mL), dried over MgSO₄, and concentrated. The residue was purified by flash column chromatography (gradient elution, 0→3% CH₃OH in CH₂Cl₂) to provide **31** (0.32 g, 44%) as a white amorphous solid: *R*_f = 0.20 (5% CH₃OH in CHCl₃); IR (cm^{–1}) 1712, 1649, 1537, 1252, 1175; ¹H NMR (DMSO-*d*₆) δ 0.79 (d, 3H, *J* = 6.6), 0.82 (d, 3H, *J* = 6.6), 1.21 (t, 3H, *J* = 7.0), 1.26–1.37 (m, 13H), 1.46–1.54 (m, 1H), 2.56–2.60 (m, 2H), 2.82–2.97 (m, 4H), 3.98–4.04 (m, 1H), 4.10 (q, 2H, *J* = 7.0), 4.42–4.49 (m, 2H), 4.98 (d, 1H, *J* = 12.5), 5.04 (d, 1H, *J* = 12.9), 5.59 (d, 1H, *J* = 15.8), 6.73–6.75 (m, 1H), 6.77 (dd, 1H, *J* = 15.8, 4.8), 7.20–7.34 (m, 10H), 7.41 (d, 1H, *J* = 8.1), 7.97 (d, 1H, *J* = 7.0), 8.07 (d, 1H, *J* = 7.0). Anal. (C₃₇H₅₃N₅O₈·0.50H₂O) C, H, N.

Ethyl-3-[Cbz-L-Leu-L-Phe-L-1-(2-imidazolidone)Ala]-E-propenoate (7). TFA (0.8 mL) was added to a solution of **31** (0.29 g, 0.42 mmol, 1 equiv) in CH₂Cl₂ (8 mL) and the reaction mixture was stirred at 23 °C for 2 h. The volatiles were then removed under reduced pressure, and the residue was dissolved in EtOAc (25 mL) and washed with saturated NaHCO₃ solution (25 mL), water (25 mL), and brine (25 mL). The organic layer was dried over MgSO₄ and was concentrated to give the crude diamine (0.23 g, 92%, 0.39 mmol) as a tan amorphous solid.

This material was dissolved in THF (4 mL) at 23 °C, and carbonyldiimidazole (0.06 g, 0.36 mmol, 0.92 equiv) was added. After being stirred for 3.5 h at 23 °C, the reaction mixture was concentrated under reduced pressure, and the residue was purified by flash column chromatography (gradient elution, 0→2% CH₃OH in CH₂Cl₂) to give **7** (0.12 g, 54%) as a white amorphous solid: mp = 161–164 °C; *R*_f = 0.21 (5% CH₃OH in CHCl₃); IR (cm^{–1}) 1701, 1647, 1535, 1277; ¹H NMR (DMSO-*d*₆) δ 0.79 (d, 3H, *J* = 6.6), 0.82 (d, 3H, *J* = 6.6), 1.21 (t, 3H, *J* = 7.0), 1.27–1.35 (m, 2H), 1.48–1.52 (m, 1H), 2.79–2.86 (m, 1H), 2.92–3.05 (m, 3H), 3.14–3.19 (m, 2H), 3.25–3.30 (m, 2H), 3.98–4.03 (m, 1H), 4.10 (q, 2H, *J* = 7.0), 4.47–4.49 (m, 1H), 4.59–4.63 (m, 1H), 4.97–5.02 (m, 2H), 5.72 (d, 1H, *J* = 15.8), 6.37 (s, 1H), 6.71 (dd, 1H, *J* = 15.8, 5.5), 7.15–7.39 (m, 10H), 7.42 (d, 1H, *J* = 8.1), 8.00 (d, 1H, *J* = 8.1), 8.18 (d, 1H, *J* = 8.1). Anal. (C₃₃H₄₃N₅O₇) C, H, N.

Ethyl-3-[(Boc-L-Phe(4-F)-L-[(N-2,4-dimethoxybenzyl)-(S)-Pyrrol-Ala]]-E-propenoate (32). A solution of HCl in 1,4-dioxane (4.0 M, 12 mL) was added to a solution of **22** (0.432 g, 0.906 mmol, 1 equiv) in the same solvent (12 mL) at 23 °C. After the mixture was stirred for 1.5 h at 23 °C, the solvent was evaporated to give the crude amine salt which was dissolved in DMF (7 mL) and cooled to 0 °C. Boc-L-Phe(4-F)-OH (0.308 g, 1.09 mmol, 1.2 equiv), *N,N*-diisopropylethylamine (0.474 mL, 2.72 mmol, 3.0 equiv), and HATU (0.379 g, 0.997 mmol, 1.1 equiv) were added sequentially, and the reaction mixture was allowed to warm to 23 °C. After 1.5 h, the mixture was diluted with MTBE (200 mL), washed with 5% KHSO₄ (20 mL) and brine (20 mL), dried over MgSO₄, and concentrated. The residue was purified by flash column chromatography (60% EtOAc in hexanes) to provide **32** (0.447 g, 77%) as a white foam: *R*_f = 0.34 (60% EtOAc in hexanes); IR (cm^{–1}) 3258, 1705, 1666; ¹H NMR (CDCl₃) δ 1.28 (t, 3H, *J* = 7.2), 1.45 (s, 9H), 1.51–1.66 (m, 2H), 1.78–1.90 (m, 1H), 2.06–2.23 (m, 2H), 2.99 (dd, 1H, *J* = 13.7, 6.2), 3.11 (dd, 1H, *J* = 13.7, 5.3), 3.17–3.23 (m, 2H), 3.80 (s, 3H), 3.81 (s, 3H), 4.18 (q, 2H, *J* = 7.2), 4.35 (s, 2H), 4.38–4.51 (m, 2H), 5.29–5.37 (m, 1H), 5.76 (d, 1H, *J* = 15.8), 6.43–6.47 (m, 2H), 6.72 (dd, 1H, *J* = 15.8, 5.3), 6.83–6.91 (m, 2H), 7.09–7.17 (m, 3H), 7.92 (br, 1H). Anal. (C₃₄H₄₄FN₃O₈) C, H, N.

Ethyl-3-{Boc-L-Val-L-Phe(4-F)-L-[(N-2,4-dimethoxybenzyl)-(S)-Pyrrol-Ala]}-E-propenoate (33). A solution of HCl in 1,4-dioxane (4.0 M, 10 mL) was added to a solution of **32** (0.425 g, 0.662 mmol, 1 equiv) in the same solvent (10 mL) at 23 °C. After the mixture was stirred for 1.5 h at 23 °C, the solvent was evaporated to give the crude amine salt. This material was combined with Boc-L-Val-OH (0.173 g, 0.796 mmol, 1.2 equiv) and dissolved in CH₂Cl₂ (20 mL) at 23 °C. HOBt (0.152 g, 1.12 mmol, 1.7 equiv), 4-methylmorpholine (0.291 mL, 2.65 mmol, 4.0 equiv), and EDC (0.216 g, 1.13 mmol, 1.7 equiv) were then added sequentially. After being stirred overnight at 23 °C, the reaction mixture was diluted with MTBE (200 mL) and washed with 5% KHSO₄ (20 mL), saturated NaHCO₃ (20 mL), and brine (20 mL). The organic layer was dried over Na₂SO₄ and was concentrated. The residue was purified by flash column chromatography (gradient elution, 60→100% EtOAc in hexanes) to provide **33** (0.430 g, 88%) as a white foam: R_f = 0.24 (60% EtOAc in hexanes); IR (cm⁻¹) 3284, 1713, 1678 br, 1643; ¹H NMR (CDCl₃) δ 0.91 (d, 3H, J = 6.8), 0.97 (d, 3H, J = 6.8), 1.28 (t, 3H, J = 7.2), 1.45 (s, 9H), 1.50–1.62 (m, 2H), 1.66–1.82 (m, 1H), 1.90–2.02 (m, 1H), 2.08–2.21 (m, 2H), 2.94 (dd, 1H, J = 13.5, 5.8), 3.17–3.27 (m, 3H), 3.80 (s, 3H), 3.82 (s, 3H), 3.97–4.05 (m, 1H), 4.17 (q, 2H, J = 7.2), 4.27 (d, 1H, J = 14.3), 4.29–4.38 (m, 1H), 4.40 (d, 1H, J = 14.3), 4.86–4.93 (m, 1H), 5.10 (d, 1H, J = 8.7), 5.76 (dd, 1H, J = 15.6, 1.2), 6.45–6.52 (m, 2H), 6.70 (dd, 1H, J = 15.6, 5.4), 6.79–6.88 (m, 3H), 7.12–7.22 (m, 3H), 8.30 (d, 1H, J = 5.9). Anal. (C₃₉H₅₃FN₅O₉) C, H, N.

Ethyl-3-{(5'-methylisoxazole-3'-carbonyl)-L-Val-L-Phe(4-F)-L-[(N-2,4-dimethoxybenzyl)-(S)-Pyrrol-Ala]}-E-propenoate (34). A solution of HCl in 1,4-dioxane (4.0 M, 10 mL) was added to a solution of **33** (0.410 g, 0.553 mmol, 1 equiv) in the same solvent (10 mL) at 23 °C. After the mixture was stirred for 1.5 h at 23 °C, the solvent was evaporated to give the crude amine salt which was dissolved in CH₂Cl₂ (20 mL) and cooled to 0 °C. 4-Methylmorpholine (0.134 mL, 1.22 mmol, 2.2 equiv) and 5-methylisoxazole-3-carbonyl chloride (0.089 g, 0.61 mmol, 1.1 equiv) were added sequentially, and the ice bath was removed. After being stirred for 1 h at 23 °C, the reaction mixture was diluted with MTBE (200 mL), washed with 5% KHSO₄ (20 mL), saturated NaHCO₃ (20 mL), and brine (20 mL), dried over Na₂SO₄, and concentrated. The residue was purified by flash column chromatography (2% CH₃OH in CH₂Cl₂) to provide **34** (0.288 g, 69%) as a white foam: R_f = 0.36 (5% CH₃OH in CH₂Cl₂); IR (cm⁻¹) 3284, 1717, 1650; ¹H NMR (CDCl₃) δ 0.97 (d, 3H, J = 6.8), 1.01 (d, 3H, J = 6.8), 1.28 (t, 3H, J = 7.2), 1.51–1.64 (m, 2H), 1.72–1.84 (m, 1H), 1.95–2.05 (m, 1H), 2.11–2.33 (m, 2H), 2.48 (s, 3H), 2.98 (dd, 1H, J = 13.7, 5.6), 3.16–3.24 (m, 3H), 3.80 (s, 3H), 3.81 (s, 3H), 4.17 (q, 2H, J = 7.2), 4.23 (d, 1H, J = 14.3), 4.31–4.42 (m, 1H), 4.40 (d, 1H, J = 14.3), 4.44–4.50 (m, 1H), 4.88–4.96 (m, 1H), 5.79 (dd, 1H, J = 15.6, 1.4), 6.43–6.49 (m, 3H), 6.71 (dd, 1H, J = 15.6, 5.3), 6.80–6.88 (m, 2H), 6.94 (d, 1H, J = 9.3), 7.11–7.17 (m, 3H), 7.29 (d, 1H, J = 8.7), 8.33 (d, 1H, J = 6.2). Anal. (C₃₉H₄₈FN₅O₉·0.50H₂O) C, H, N.

Ethyl-3-{(5'-methylisoxazole-3'-carbonyl)-L-Val-L-Phe(4-F)-L-[(S)-Pyrrol-Ala]}-E-propenoate (9). A suspension of **34** (0.263 g, 0.351 mmol, 1 equiv), water (2 drops), and DDQ (0.104 g, 0.458 mmol, 1.3 equiv) in CHCl₃ (10 mL) was refluxed for 9 h and then allowed to cool to room temperature over 8 h. The reaction mixture was diluted with CH₂Cl₂ (200 mL) and washed with a 2:1 mixture of saturated NaHCO₃ and 1 M NaOH (20 mL). The organic phase was dried over MgSO₄ and was concentrated. Purification of the residue by flash column chromatography (gradient elution, 2→3% CH₃OH in CH₂Cl₂) gave **9** (0.117 g, 56%) as a white solid: mp = 219–220 °C; R_f = 0.23 (5% CH₃OH in CH₂Cl₂); IR (cm⁻¹) 3401 br, 3295, 1655 br; ¹H NMR (CDCl₃) δ 0.94 (d, 3H, J = 6.8), 0.97 (d, 3H, J = 6.5), 1.29 (t, 3H, J = 7.2), 1.54–1.65 (m, 1H), 1.72–1.91 (m, 2H), 2.07–2.26 (m, 2H), 2.28–2.39 (m, 1H), 2.49 (d, 3H, J = 0.9), 3.01 (dd, 1H, J = 13.8, 6.1), 3.12 (dd, 1H, J = 13.8, 6.4), 3.26–3.38 (m, 2H), 4.18 (q, 2H, J = 7.2), 4.34 (dd, 1H, J = 8.7, 7.2), 4.43–4.54 (m, 1H), 4.90 (dt, 1H, J = 9.0, 6.2), 5.76 (dd, 1H, J = 15.6, 1.6), 6.00 (s, 1H), 6.42 (q, 1H, J = 0.9), 6.72

(dd, 1H, J = 15.6, 5.4), 6.86–6.94 (m, 2H), 7.01 (d, 1H, J = 9.0), 7.11–7.18 (m, 2H), 7.21 (d, 1H, J = 8.7), 7.76 (d, 1H, J = 7.2). Anal. (C₃₀H₃₈FN₅O₇) C, H, N.

Ethyl-3-{Boc-L-ValΨ[COCH₂]-L-Phe(4-F)-L-[(N-2,4-dimethoxybenzyl)-(S)-Pyrrol-Ala]}-E-propenoate (36). A solution of HCl in 1,4-dioxane (4.0 M, 10 mL) was added to a solution of **22** (0.342 g, 0.718 mmol, 1 equiv) in the same solvent (10 mL) at 23 °C. After the mixture was stirred for 1.5 h at that temperature, the volatiles were removed under reduced pressure to give the crude amine salt. This material was combined with crude **35**⁸ (1.00 mmol, 1.4 equiv) and dissolved in CH₂Cl₂ (17 mL) at 23 °C. HOBt (0.165 g, 1.22 mmol, 1.7 equiv) and EDC (0.234 g, 1.22 mmol, 1.7 equiv) were added sequentially. After stirring overnight at 23 °C, the reaction mixture was partitioned between brine (30 mL) and a 1:9 mixture of CH₃OH and CH₂Cl₂ (3 × 70 mL). The organic layers were dried over Na₂SO₄ and were concentrated. The residue was purified by flash column chromatography (55% EtOAc in hexanes) to provide **36** (0.337 g, 63%) as a white foam: R_f = 0.24 (60% EtOAc in hexanes); IR (cm⁻¹) 3293, 1717, 1668; ¹H NMR (CDCl₃) δ 0.82 (d, 3H, J = 6.8), 1.01 (d, 3H, J = 6.8), 1.30 (t, 3H, J = 7.2), 1.51–1.65 (m, 2H), 1.84–1.96 (m, 1H), 2.16–2.37 (m, 2H), 2.47 (s, 3H), 2.49–2.55 (m, 3H), 2.85–3.01 (m, 2H), 3.12–3.25 (m, 3H), 3.77 (s, 3H), 3.78 (s, 3H), 4.18 (q, 2H, J = 7.2), 4.31–4.49 (m, 3H), 4.65–4.70 (m, 1H), 5.53 (dd, 1H, J = 15.7, 1.4), 6.39–6.44 (m, 3H), 6.63 (dd, 1H, J = 15.7, 5.4), 6.93–7.01 (m, 2H), 7.05–7.10 (m, 1H), 7.12–7.18 (m, 2H), 7.24 (d, 1H, J = 8.7), 7.47 (d, 1H, J = 6.5). Anal. (C₄₀H₅₄FN₃O₉·0.50H₂O) C, H, N.

Ethyl-3-{(5'-methylisoxazole-3'-carbonyl)-L-ValΨ[COCH₂]-L-Phe(4-F)-L-[(N-2,4-dimethoxybenzyl)-(S)-Pyrrol-Ala]}-E-propenoate (37). A solution of HCl in 1,4-dioxane (4.0 M, 5 mL) was added to a solution of **36** (0.309 g, 0.418 mmol, 1 equiv) in the same solvent (5 mL) at 23 °C. After the mixture was stirred for 1.5 h at 23 °C, the volatiles were removed under reduced pressure to give the crude amine salt. This material was dissolved in CH₂Cl₂ (15 mL) and cooled to 0 °C. 4-Methylmorpholine (0.101 mL, 0.919 mmol, 2.2 equiv) and 5-methylisoxazole-3-carbonyl chloride (0.067 g, 0.46 mmol, 1.1 equiv) were added sequentially, and the ice bath was removed. After being stirred for 1 h at 23 °C, the reaction mixture was partitioned between brine (15 mL) and a 1:9 mixture of CH₃OH and CH₂Cl₂ (3 × 30 mL). The organic layers were dried over Na₂SO₄ and were concentrated. The residue was purified by flash column chromatography (70% EtOAc in hexanes) to provide **37** (0.266 g, 85%) as a white foam: R_f = 0.24 (60% EtOAc in hexanes); IR (cm⁻¹) 3293, 1717, 1668; ¹H NMR (CDCl₃) δ 0.82 (d, 3H, J = 6.8), 1.01 (d, 3H, J = 6.8), 1.30 (t, 3H, J = 7.2), 1.51–1.65 (m, 2H), 1.84–1.96 (m, 1H), 2.16–2.37 (m, 2H), 2.47 (s, 3H), 2.49–2.55 (m, 3H), 2.85–3.01 (m, 2H), 3.12–3.25 (m, 3H), 3.77 (s, 3H), 3.78 (s, 3H), 4.18 (q, 2H, J = 7.2), 4.31–4.49 (m, 3H), 4.65–4.70 (m, 1H), 5.53 (dd, 1H, J = 15.7, 1.4), 6.39–6.44 (m, 3H), 6.63 (dd, 1H, J = 15.7, 5.4), 6.93–7.01 (m, 2H), 7.05–7.10 (m, 1H), 7.12–7.18 (m, 2H), 7.24 (d, 1H, J = 8.7), 7.47 (d, 1H, J = 6.5). Anal. (C₄₀H₄₉FN₃O₉·0.50H₂O) C, H, N.

Ethyl-3-{(5'-methylisoxazole-3'-carbonyl)-L-ValΨ[COCH₂]-L-Phe(4-F)-L-[(S)-Pyrrol-Ala]}-E-propenoate (11). A suspension of DDQ (0.102 g, 0.449 mmol, 1.4 equiv), **37** (0.240 g, 0.320 mmol, 1 equiv), and water (2 drops) in CHCl₃ (10 mL) was refluxed for 20 h and then allowed to cool. The reaction mixture was diluted with CH₂Cl₂ (200 mL) and washed with a 2:1 mixture of saturated NaHCO₃ and 1 M NaOH (20 mL). The organic phase was dried over Na₂SO₄ and was concentrated. Purification of the residue by flash column chromatography (2% CH₃OH in CH₂Cl₂) gave **11** (0.074 g, 39%) as a faintly yellow solid: mp = 178–181 °C; R_f = 0.49 (10% CH₃OH in CHCl₃); IR (cm⁻¹) 3295, 1678 br; ¹H NMR (CDCl₃) δ 0.85 (d, 3H, J = 6.8), 1.03 (d, 3H, J = 6.5), 1.30 (t, 3H, J = 7.2), 1.51–1.62 (m, 1H), 1.71–1.93 (m, 2H), 2.27–2.40 (m, 2H), 2.47 (s, 3H), 2.51–2.75 (m, 3H), 2.82–2.98 (m, 2H), 3.11–3.24 (m, 1H), 3.26–3.42 (m, 2H), 4.18 (q, 2H, J = 7.2), 4.41–4.53 (m, 1H), 4.63–4.72 (m, 1H), 5.50 (d, 1H, J = 15.4), 5.88 (s,

1H), 6.39 (s, 1H), 6.63 (dd, 1H, $J = 15.4, 5.3$), 6.92–7.03 (m, 2H), 7.08–7.31 (m, 4H). Anal. (C₃₁H₃₉FN₄O₇) C, H, N.

Protease Selectivity Assays. Assays were performed using commercially available proteases (at ~10 nM concentrations) essentially as described by the supplier. Human liver cathepsin B, porcine erythrocyte calpain I, and human neutrophil elastase were purchased from Calbiochem. Bovine chymotrypsin and human thrombin were purchased from Boehringer Mannheim. Bovine trypsin was purchased from Sigma.

Degradation Studies of Compound 11. Compound 11 (25 μ M) and 100 mM potassium phosphate buffer (pH 7.4) were preincubated in test tubes for 5 min at 37 °C in a shaking water bath. Chymotrypsin (Sigma, 5 units/mL) or porcine intestinal peptidase (Sigma, 0.1 units/mL) was preincubated at 37 °C and then added to the appropriate test tube containing 11 to initiate the reaction. After 0 and 60 min, a 200 μ L aliquot of each incubation mixture was transferred to a microcentrifuge tube containing 200 μ L of CH₃CN. These tubes were capped, vortexed, and centrifuged in an Eppendorf (Hamburg) 5415C centrifuge at 14 000 rpm for 10 min. A 15 μ L portion of each supernatant was then injected onto a Hewlett-Packard 1100 HPLC equipped with a Zorbax RX C8 (2.1 m \times 150 mm) column (DuPont, Wilmington, DE). The aqueous component of the mobile phase was 0.1% Et₃N in water adjusted to pH 3.5 with approximately 0.05% trifluoroacetic acid. Compound 11 was eluted using a solvent gradient beginning with 55:25:20 buffer:CH₃CN:CH₃OH, increasing to 20:60:20 buffer:CH₃CN:CH₃OH over 10 min and held for 10 min before returning to the original conditions at a flow rate of 0.3 mL/min. Compound 11 was detected by UV at 220 nm. The hydrolysis of 1-naphthyl butyrate served as a positive control for the esterase activity of the peptidase under study.

Plasma Stability Studies of Compound 11. Human plasma anticoagulated with CPDA (citrate phosphate dextrose adenine) was obtained from the San Diego Blood Bank, San Diego, CA. Heparinized plasma from several animal species was purchased from Covance Research, Denver, PA. The plasma was distributed into 5 mL cryotubes and frozen at –70 °C until analysis. In preparation for the experiment, 1990 μ L of plasma ($n = 3$) or 1990 μ L of 100 mM potassium phosphate pH 7.4 buffer ($n = 3$) were placed into separate test tubes. Because of enhanced plasma esterase activity relative to that of other species, rat plasma was diluted 1:1 with 100 mM potassium phosphate pH 7.4 buffer ($n = 3$) prior to the experiments. All tubes were preincubated in a shaking water bath for a few minutes until the solutions had reached 37 °C. At the start of the incubation, 10 μ L of a freshly made 5 mM solution of compound 11 in CH₃CN was pipetted into a test tube containing plasma or buffer to achieve a final concentration of 25 μ M. After vortexing the tube, a 200 μ L sample was collected, and the tube was returned to the water bath. The test tubes were then incubated at 37 °C and 200 μ L samples were collected periodically for 1 h. These samples were immediately transferred to borosilicate tubes prefilled with 2.0 mL of CH₃CN, and the mixtures were vortexed to ensure protein precipitation and termination of metabolic transformations. After subsequent centrifugation for 10 min at 4000 rpm at 10 °C in a Sorvall RT 7 centrifuge, the clear supernatant was decanted into a new set of borosilicate tubes and the volatiles were removed under a gentle stream of nitrogen using a Dri-Block sample concentrator (Techne, Princeton, NJ) at 40 °C. The samples were reconstituted in 250 μ L of mobile phase (60% 25 mM NH₄H₂PO₄ at pH = 5.1 and 40% CH₃CN) and subjected to HPLC analysis.

Chromatographic analyses were performed using a 1100 Hewlett-Packard HPLC with a Primesphere reversed phase column (5 μ m, 4.6 m \times 150 mm, Phenomenex, Torrance, CA) at flow rate 1 mL/min and a gradient elution of NH₄H₂PO₄ 25 mM buffer, pH = 5.1/CH₃CN/CH₃OH (95/3/2 to 70/28/2 over 5 min, changing to 50/48/2 over the next 5 min, and reverting to 95/3/2 for the final 5 min). A sample volume of 100 μ L was injected onto the column, and compound 11 was detected by UV absorption at 212 nm utilizing a Hewlett-Packard multi-

wavelength detector. The standard curve for compound 11 ranged from 0.05 μ g/mL to 40.0 μ g/mL. Using the above HPLC conditions, the retention time for compound 11 was approximately 13 min. The hydrolysis of 1-naphthyl butyrate served as a positive control for carboxyl esterase activity in human plasma.

Molecular Modeling Studies. A simple computational approach was employed to estimate the binding free energies of complexes formed between the HRV 3C protein (P) and various ligands (L). This approach assumes that a single protein–ligand conformation predominates in the bound complex while another dominates in solution. The protein–ligand association was expressed as a two-step process involving hypothetical bound conformations of the ligand and protein in solution, where the binding energy is given by the sum of an interaction term and two strain energies (eq 1). Unlike free

$$\begin{aligned}\Delta G &= E_{LP}^{\text{bound}} - E_L^{\text{unbound}} - E_P^{\text{unbound}} \\ &= [E_{LP}^{\text{bound}} - E_L^{\text{bound}} - E_P^{\text{bound}}] + [E_L^{\text{bound}} - E_L^{\text{unbound}}] + [E_P^{\text{bound}} - E_P^{\text{unbound}}] \\ &= \Delta E_{LP}^{\text{interaction}} + \Delta E_L^{\text{strain}} + \Delta E_P^{\text{strain}}\end{aligned}\quad (1)$$

energy perturbation methods, this approach neglects entropic contributions to binding affinity and represents a zero-temperature enthalpic estimate for the binding free energy. A simple entropic correction was therefore applied to the calculated binding affinities of the noncovalent encounter complexes to account for this fact.²¹

The binding energy of the complex was obtained by local minimization using the Amber* force field and GB/SA solvation correction contained in the MacroModel (v5.5) software package.³¹ The ligand was assigned partial charges and minimized in an enzyme active site that was reduced to 631 atoms to allow truncated-Newton conjugate gradient (TNCG) minimization. Constraints to the protein were applied in concentric spheres with atoms far from the ligand fixed rigidly in their crystallographic positions. Atoms near the ligand were constrained with increasing flexibility, utilizing a harmonic force constant of 400 kJ/Å at the outer edge of the site, 200 kJ/Å between 10 and 15 Å from the ligand, 10 kJ/Å between 5 and 10 Å from the ligand, and no constraints on atoms less than 5 Å from the ligand. The strain energies were obtained in an analogous manner.

Method No. 1. A minimized model of the covalent adduct between the glutamine-derived compound 1 and HRV 3CP was prepared using the HRV-2 3CP-1 cocrystal structure.⁵ Covalent models of the lactam-containing molecules 4, 5, and 6 were similarly constructed. Nonbonded protein–ligand interactions were assumed to determine binding trends in the series. No additional constraints were applied to the covalent connection between the protein and the ligand since bond-making and bond-breaking terms were assumed to cancel for each ligand.

Method No. 2. Noncovalent encounter complexes between HRV 3CP and compounds 1, 4, 5, and 6 were constructed from the HRV-2 3CP-1 co-crystal structure⁵ and were investigated as described above. For these complexes, an entropic correction²¹ was applied to the calculated binding affinities.

Acknowledgment. We are grateful for many helpful discussions throughout the course of this work with Prof. Larry Overman and Dr. Steven Bender. We also thank Dr. Kim Albizati, Dr. Srinivasan Babu, Terence Moran, Ray Dagnino, and Miguel Pagan for the large-scale preparation of several intermediates.

References

- (1) (a) Couch, R. B. In *Fields Virology*, 3rd ed.; Fields, B. N., Knipe, D. M., Howley, P. M., et al., Eds.; Lippincott-Raven Publishers: Philadelphia, 1996; Vol. 1, Chapter 23, pp 713–734. (b) McKinlay, M. A.; Pevear, D. C.; Rossmann, M. G. *Annu. Rev.*

- Microbiol.* **1992**, 46, 635. (c) Philippotts, R. J.; Tyrrell, D. A. J. *Br. Med. Bull.* **1985**, 41, 386. (d) Gwaltney, J. M. In *Principles and Practices of Infectious Diseases*; Mandell, G. L., Douglas, R. G., Bennett, J. E., Eds.; John Wiley & Sons: New York, 1985; Chapter 38, pp 351–355. (e) Gwaltney, J. M. In *Viral Infections of Humans*; Evans, A. S., Ed.; Plenum Publishing Corp.: New York, 1982; Chapter 20, pp 491–517.
- (2) (a) Rueckert, R. R. In *Fields Virology*, 3rd ed.; Fields, B. N., Knipe, D. M., Howley, P. M., et al., Eds.; Lippincott-Raven Publishers: Philadelphia, 1996; Vol. 1, Chapter 21, pp 609–654. (b) Kräusslich, H.-G.; Wimmer, E. *Annu. Rev. Biochem.* **1988**, 57, 701.
- (3) (a) Cordingley, M. G.; Callahan, P. L.; Sardana, V. V.; Garsky, V. M.; Colonno, R. J. Substrate Requirements of Human Rhinovirus 3C Protease for Peptide Cleavage in Vitro. *J. Biol. Chem.* **1990**, 265, 9062–9065. (b) Orr, D. C.; Long, A. C.; Kay, J.; Dunn, B. M.; Cameron, J. M. Hydrolysis of a Series of Synthetic Peptide Substrates by the Human Rhinovirus 14 3C Proteinase, Cloned and Expressed in *Escherichia coli*. *J. Gen. Virol.* **1989**, 70, 2931–2942. (c) Cordingley, M. G.; Register, R. B.; Callahan, P. L.; Garsky, V. M.; Colonno, R. J. Cleavage of Small Peptides In Vitro by Human Rhinovirus 14 3C Protease Expressed in *Escherichia coli*. *J. Virol.* **1989**, 63, 5037–5045.
- (4) The nomenclature used for describing the individual amino acid residues of a peptide substrate (P_2 , P_1 , P_1' , P_2' , etc.) and the corresponding enzyme subsites (S_2 , S_1 , S_1' , S_2' , etc.) is described in the following: Schechter, I.; Berger, A. On the Size of the Active Site in Proteases. I. Papain. *Biochem. Biophys. Res. Commun.* **1967**, 27, 157–162.
- (5) Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Lee, C. A.; Reich, S. R.; Prins, T. J.; Marakovits, J. T.; Littlefield, E. S.; Zhou, R.; Tikhe, J.; Ford, C. E.; Wallace, M. B.; Meador, J. W., III; Ferre, R. A.; Brown, E. L.; Binford, S. L.; Harr, J. E. V.; DeLisle, D. M.; Worland, S. T. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structure–Activity Studies. *J. Med. Chem.* **1998**, 41, 2806–2818.
- (6) Dragovich, P. S.; Webber, S. E.; Babine, R. E.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Reich, S. H.; Marakovits, J. T.; Prins, T. J.; Zhou, R.; Tikhe, J.; Littlefield, E. S.; Bleckman, T. M.; Wallace, M. B.; Little, T. L.; Ford, C. E.; Meador, J. W., III; Ferre, R. A.; Brown, E. L.; Binford, S. L.; DeLisle, D. M.; Worland, S. T. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure–Activity Studies. *J. Med. Chem.* **1998**, 41, 2819–2834.
- (7) A similar series of HRV 3CP inhibitors has also recently been described. See: Kong, J.-s.; Venkatraman, S.; Furness, K.; Nimkar, S.; Shepherd, T. A.; Wang, Q. M.; Aubé, J.; Hanzlik, R. P. Synthesis and Evaluation of Peptidyl Michael Acceptors That Inactivate Human Rhinovirus 3C Protease and Inhibit Virus Replication. *J. Med. Chem.* **1998**, 41, 2579–2587.
- (8) Preceding paper in this issue. Dragovich, P. S.; Prins, T. J.; Zhou, R.; Fuhrman, S. A.; Patick, A. K.; Matthews, D. A.; Ford, C. E.; Meador, J. W., III; Ferre, R. A.; Worland, S. T. Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 3. Structure–Activity Studies of Ketomethylene-Containing Peptidomimetics. *J. Med. Chem.* **1999**, 42, 1203–1212.
- (9) All amino acids described in the text are L-isomers unless otherwise noted.
- (10) Note that the reduction in the antiviral potency of **2** (or **3**) relative to **1** was not nearly as great as the loss in 3CP inhibition activity. This observation suggested that Gln amide N-alkylation may result in improved cell permeability properties.
- (11) The loss in anti-3CP activity of **2** relative to **1** was approximately equal to the expected energetic difference between the *cis* and *trans* amide isomers of **2** (2.2 kcal/mol extrapolated from measured $k_{\text{obs}}/[I]$ values vs 2.6 kcal/mol reported for simple model systems).¹² This analysis assumes that changes in $k_{\text{obs}}/[I]$ values approximate changes in ligand–3CP binding affinity and that the anti-3CP activities of *cis*- and *trans*-**2** are similar to those displayed by compounds **1** and **3**, respectively.
- (12) Jorgensen, W. L.; Gao, J. *Cis–Trans Energy Difference for the Peptide Bond in the Gas Phase and in Aqueous Solution*. *J. Am. Chem. Soc.* **1988**, 110, 4212–4216 and references therein.
- (13) In several cases, the solubility of a given inhibitor was determined to be less than the reported CC_{50} value. However, the most active antiviral agents were clearly soluble and nontoxic to more than 10 \times the reported EC_{50} values.
- (14) Analysis of the HRV-2 3CP-**8** X-ray crystal structure showed that the lactam-containing inhibitor **8** bound to 3CP in a manner nearly identical to that observed previously⁵ for the glutamine-derived molecule **1** (Matthews, D. A. Unpublished results).
- (15) Dragovich, P. S.; Zhou, R.; Skaltitzky, D. J.; Fuhrman, S. A.; Patick, A. K.; Ford, C. E.; Meador, J. W., III; Worland, S. T. Solid-Phase Synthesis of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Optimization of Tripeptides Incorporating N-Terminal Amides. *Bioorg. Med. Chem.*, in press.
- (16) The antirhinoviral properties of certain 3CP inhibitors were determined against several additional HRV serotypes in cell culture. In general, the activity observed for a given compound vs serotypes 1A, 2, and 10 was representative of its broad-spectrum antiviral properties. Serotype 14 nearly always proved to be the most susceptible to the antiviral agents under study. Compound **11** (AG7088) has been tested against 46 HRV serotypes to date and is active against all with a mean EC_{90} of approximately 0.10 μ M. Full details of these experiments will be presented elsewhere (Patick, A. K. Manuscript in preparation).
- (17) Andries, K.; Dewindt, B.; Snoeks, J.; Willebrords, R.; Van Eemeren, K.; Stokbroekx, R.; Janssen, P. A. J. In Vitro Activity of Pirodavir (R 77975), a Substituted Phenoxy-Pyridazinamine with Broad-Spectrum Antipicornaviral Activity. *Antimicrob. Agents Chemother.* **1992**, 36, 100–107.
- (18) (a) Diana, G. D.; Rudewicz, P.; Pevear, D. C.; Nitz, T. J.; Aldous, S. C.; Aldous, D. J.; Robinson, D. T.; Draper, T.; Dutko, F. J.; Aldi, C.; Gendron, G.; Oglesby, R. C.; Volkots, D. L.; Reuman, M.; Bailey, T. R.; Czerniak, R.; Block, T.; Roland, R.; Oppermann, J. Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism. *J. Med. Chem.* **1995**, 38, 1355–1371. (b) Fromling, R. A.; Castañer, J. V. *JP-63843*. *Drugs Future* **1997**, 22, 40–44.
- (19) The α,β -unsaturated carboxylic acids corresponding to the compounds in Table 3 are assumed to exhibit drastically reduced antirhinoviral activity by analogy to data obtained for inhibitor **1**. See ref 5 for additional details.
- (20) The assumption that rat plasma degradation of **11** primarily affords the corresponding α,β -unsaturated carboxylic acid is based on the related degradation of compound **1**. See ref 5 for additional details.
- (21) Mammen, M.; Shakhnovich, E. I.; Whitesides, G. M. Using a Convenient, Quantitative Model for Torsional Entropy To Establish Qualitative Trends for Molecular Processes That Restrict Conformational Freedom. *J. Org. Chem.* **1998**, 63, 3168–3175.
- (22) Chida, N.; Tobe, T.; Okada, S.; Ogawa, S. Total Synthesis and Absolute Configuration of Bengamide A. *J. Chem. Soc., Chem. Commun.* **1992**, 1064–1066.
- (23) Ho, G.-J.; Mathre, D. Lithium-Initiated Imide Formation. A Simple Method for N-Acylation of 2-Oxazolidinones and Bornane-2,10-Sultam. *J. Org. Chem.* **1995**, 60, 2271–2273.
- (24) Evans, D. A.; Rieger, D. L.; Jones, T. K.; Kaldor, S. W. Assignment of Stereochemistry in the Oligomycin/Rutamycin/Cytovaricin Family of Antibiotics. Asymmetric Synthesis of the Rutamycin Spiroketal Synthons. *J. Org. Chem.* **1990**, 55, 6260–6268 and references therein.
- (25) The diastereomeric excess obtained in the preparation of **18** was not rigorously determined, but it is inferred to be high based on literature precedent²⁴ and the absence of significant (>10%) diastereomers in the ^1H NMR spectra of **18** and subsequent synthetic intermediates.
- (26) (a) Mancuso, A. J.; Swern, D. Activated Dimethyl Sulfoxide: Useful Reagents for Synthesis. *Synthesis* **1981**, 165–185. (b) Tidwell, T. T. Oxidation of Alcohols by Activated Dimethyl Sulfoxide and Related Reactions: An Update. *Synthesis* **1990**, 857–870. (c) DeCamp, A. E.; Kawaguchi, A. T.; Volante, R. P.; Shinkai, I. Stereocontrolled Addition of Propionate Homoenolate Equivalents to Chiral α -Amino Aldehydes. *Tetrahedron Lett.* **1991**, 32, 1867–1870.
- (27) Mori, S.; Iwakura, H.; Takechi, S. A New Amidoalkynylation Using Alkynylzinc Reagent. *Tetrahedron Lett.* **1988**, 29, 5391–5394 and references therein.
- (28) Overman, L. E.; Osawa, T. A Convenient Synthesis of 4-Unsubstituted β -Lactams. *J. Am. Chem. Soc.* **1985**, 107, 1698–1701 and references therein.
- (29) During the preparation of **6**, the diastereomeric excess of the allylic alkylation product corresponding to **18** was also not rigorously determined. See ref 25 above.
- (30) Webber, S. E.; Okano, K.; Little, T. L.; Reich, S. H.; Xin, Y.; Fuhrman, S. A.; Matthews, D. A.; Hendrickson, T. F.; Love, R. A.; Patick, A. K.; Meador, J. W., III; Ferre, R. A.; Brown, E. L.; Ford, C. E.; Binford, S. L.; Worland, S. T. Tripeptide Aldehyde Inhibitors of Human Rhinovirus 3C Protease: The Design, Synthesis, Biological Evaluation and Cocystal Structure Solution of P_1 Glutamine Isosteric Replacements. *J. Med. Chem.* **1998**, 41, 2786–2805.
- (31) Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel-An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. *J. Comput. Chem.* **1990**, 11, 440–467.